HC Wainwright Begins Coverage on Intellia Therapeutics (NASDAQ:NTLA)

Equities researchers at HC Wainwright began coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 203.03% from the company’s current price. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.43) EPS and Q4 2026 earnings at ($1.17) EPS.

Several other brokerages have also recently issued reports on NTLA. Oppenheimer reduced their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Truist Financial reduced their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. Wedbush restated a “neutral” rating and issued a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Chardan Capital reduced their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Finally, StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $9.90 on Wednesday. The company’s fifty day moving average price is $10.64 and its 200-day moving average price is $15.28. Intellia Therapeutics has a 1-year low of $8.30 and a 1-year high of $32.00. The firm has a market capitalization of $1.02 billion, a PE ratio of -1.82 and a beta of 1.97.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock worth $352,551. Corporate insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of large investors have recently made changes to their positions in NTLA. Harbor Capital Advisors Inc. grew its position in Intellia Therapeutics by 71.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock valued at $1,628,000 after buying an additional 32,893 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after acquiring an additional 659,651 shares in the last quarter. Lewis Asset Management LLC increased its stake in shares of Intellia Therapeutics by 42.5% during the third quarter. Lewis Asset Management LLC now owns 66,308 shares of the company’s stock worth $1,363,000 after acquiring an additional 19,775 shares during the period. Atria Investments Inc lifted its position in Intellia Therapeutics by 24.3% in the third quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock valued at $475,000 after purchasing an additional 4,511 shares during the period. Finally, Privium Fund Management B.V. purchased a new stake in Intellia Therapeutics in the 3rd quarter valued at approximately $253,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.